Novartis Beats on Q3 Earnings and Sales, Raises 2024 Outlook
Novartis(NVS) ZACKS·2024-10-29 23:25
Swiss pharma giant Novartis AG (NVS) reported better-than-expected results for the third quarter of 2024. Core earnings (excluding one-time charges) of $2.06 per share beat the Zacks Consensus Estimate of $1.94 and were up from $1.74 reported a year ago. The year-over-year growth was driven by an increase in sales. Revenues of $12.8 billion climbed 9% from the year-ago figure. On a constant currency basis, sales increased 10%, driven by the momentum in Entresto, Kesimpta, Kisqali, Cosentyx, Pluvicto and Leq ...